Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,798
  • Shares Outstanding, K 4,310
  • Annual Sales, $ 400 K
  • Annual Income, $ -16,950 K
  • 36-Month Beta 1.89
  • Price/Sales 107.28
  • Price/Cash Flow N/A
  • Price/Book 1.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.90 +114.08%
on 11/16/17
10.65 -1.50%
on 12/15/17
+5.60 (+114.52%)
since 11/15/17
3-Month
3.80 +176.05%
on 09/19/17
10.65 -1.50%
on 12/15/17
+6.54 (+165.57%)
since 09/15/17
52-Week
3.11 +237.30%
on 08/24/17
18.88 -44.44%
on 03/28/17
-5.56 (-34.64%)
since 12/15/16

Most Recent Stories

More News
Today's Research Reports on Trending Tickers: Catalyst Biosciences and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower,...

CBIO : 10.49 (+5.64%)
VRX : 19.71 (+0.15%)
Catalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors

Former Novo Nordisk Executive Strengthens Catalyst's Hemophilia Expertise

NVO : 52.51 (-0.66%)
CBIO : 10.49 (+5.64%)
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours

CBIO : 10.49 (+5.64%)
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours

CBIO : 10.49 (+5.64%)
Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team

-- Appoints Arwa Shurrab as Vice President of Regulatory Affairs and Jamie Ellen Siegel, M.D., as Head of Clinical Development --

CBIO : 10.49 (+5.64%)
Today's Research Reports on Trending Tickers: Catalyst Biosciences and Corcept Therapeutics

NEW YORK, NY / ACCESSWIRE / November 20, 2017 / U.S. markets closed in the red Friday, with the Dow Jones and S&P 500 posting their second consecutive weekly loss, as concerns regarding President Trump's...

CORT : 16.61 (-3.82%)
CBIO : 10.49 (+5.64%)
Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update

-- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end --

CBIO : 10.49 (+5.64%)
Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology

CB 2679d demonstrated a 22-fold greater potency over BeneFIX and a longer mean residence time

CBIO : 10.49 (+5.64%)
LifeSci Advisors Announces 11th Board Appointment Through Board Placement Initiative

LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, announced today the 11th placement of a female executive to a life sciences company board...

CBIO : 10.49 (+5.64%)
LifeSci Advisors Announces 11th Board Appointment Through Board Placement Initiative

NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, announced today the 11th placement of a female...

CBIO : 10.49 (+5.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Key Turning Points

2nd Resistance Point 11.16
1st Resistance Point 10.83
Last Price 10.49
1st Support Level 9.98
2nd Support Level 9.46

See More

52-Week High 18.88
Fibonacci 61.8% 12.86
Fibonacci 50% 10.99
Last Price 10.49
Fibonacci 38.2% 9.13
52-Week Low 3.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.